Cabotib 60MG Tablet (30’s) is a prescription medication that contains Cabozantinib as its active ingredient, specifically formulated to treat certain types of cancer. This drug is primarily indicated for patients with advanced renal cell carcinoma (kidney cancer) and hepatocellular carcinoma (liver cancer) who have previously undergone other treatments. Cabozantinib works by inhibiting multiple receptor tyrosine kinases, which are involved in tumor growth and metastasis, thereby slowing down the progression of cancer. Each tablet contains 60 mg of Cabozantinib, and the medication is typically prescribed as part of a comprehensive cancer treatment plan. Patients taking Cabotib should be closely monitored for side effects and treatment efficacy, making it essential to follow the healthcare provider’s instructions carefully.

Cabotib 40MG Tablet (30’s) is a prescription medication that contains Cabozantinib as its active ingredient, specifically formulated to treat certain types of cancer. This drug is primarily indicated for patients with advanced renal cell carcinoma (kidney cancer) and hepatocellular carcinoma (liver cancer) who have previously undergone other treatments. Cabozantinib works by inhibiting multiple receptor tyrosine kinases, which are involved in tumor growth and progression, thereby helping to slow down the spread of cancer cells. Each tablet contains 40 mg of Cabozantinib, and the medication is typically available in a pack of 30 tablets. The drug is designed to be taken orally, making it convenient for patients to incorporate into their daily routines. As a targeted therapy, Cabotib aims to improve patient outcomes by specifically addressing the pathways that contribute to cancer development, thus offering a more effective treatment option for those battling these serious conditions.

Cabotib 20MG Tablet (30’s) is a pharmaceutical product containing Cabozantinib as its active ingredient, specifically formulated to treat certain types of cancer. This medication is primarily indicated for patients with advanced renal cell carcinoma (kidney cancer) and hepatocellular carcinoma (liver cancer) who have previously undergone treatment. Cabozantinib works by inhibiting multiple receptor tyrosine kinases, which are involved in tumor growth and progression, thereby helping to slow down the spread of cancer cells. Each tablet contains 20 mg of Cabozantinib, and the packaging typically includes 30 tablets, making it convenient for patients to manage their treatment regimen. The drug is designed to be taken orally, and its effectiveness is enhanced when used as part of a comprehensive cancer treatment plan, which may include other therapies and supportive care.